PTH and osteoporosis: FDA-approved therapies against osteoporosis include bisphosphonates, which bind to the bone mineral surface and inhibit osteoclast-mediated bone resorption [49], and teriparatide (the amino terminal region of PTH) which acts as an anabolic agent by promoting new bone formation and, reducing the risk of vertebral and hip fractures [50, 51].